サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1642692

ジェネリック注入剤市場レポート：治療領域、容器、流通チャネル、地域別、2025年～2033年

Generic Injectables Market Report by Therapeutic Area, Container, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 125 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ジェネリック注入剤市場レポート：治療領域、容器、流通チャネル、地域別、2025年～2033年
出版日: 2025年01月18日
発行: IMARC
ページ情報: 英文 125 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ジェネリック注入剤市場の世界市場規模は2024年に510億米ドルに達しました。IMARC Groupは、2025年から2033年にかけての成長率（CAGR）は6.88%で、2033年には992億米ドルに達すると予測しています。ブランド医薬品の特許切れが進んでいることに加え、政府機関による規制支援が増加していることが、主に市場を牽引しています。

ジェネリック注入剤とは、体内に注入される医薬品で、用量、強度、品質、性能において先発医薬品と同等であるものを指します。ワクチン、インスリン、抗生物質など様々な種類があります。ジェネリック注入剤は、糖尿病、がん、高血圧、感染症など、さまざまな病状に広く使用されています。また、麻酔、ホルモン補充、予防接種、緊急治療などにも幅広く使用されています。ジェネリック注入剤は、外科的介入の必要性を減らし、的を絞った治療を提供し、副作用が少ない、安全で費用対効果の高い薬剤です。

ドラッグ製剤とドラッグデリバリー・システムにおける最近の技術進歩は、生産をより効率的にし、それによってコストを下げ、入手可能性を高めており、市場の成長を後押ししています。さらに、承認プロセスを合理化することにより、ジェネリック注入剤メーカーにとって好都合な環境を作るための様々な規制支援やイニシアチブの実施が、市場の成長に寄与しています。これとは別に、様々な加齢に関連した疾患のために注射剤を含むより多くのヘルスケア介入を必要とする老人人口の増加が、市場成長にプラスの影響を与えています。さらに、即効性と生物学的利用能の高さから、患者の間で経口薬よりも注射薬への嗜好が高まっていることも、市場の成長を強めています。さらに、サプライチェーンの急速な改善により、ジェネリック注入剤の流通がより合理化されていることも、市場の成長を支えています。

ジェネリック注入剤市場傾向/促進要因：

慢性疾患の増加

慢性疾患の蔓延は、ジェネリック注入剤市場の主要なドライバーです。がん、糖尿病、心血管疾患（CVDs）などの治療は増加の一途をたどっており、長期にわたる治療や投薬が必要です。糖尿病のインスリン、がんの化学療法剤、心血管疾患の降圧剤などのジェネリック注入剤は、これらの疾患の管理に不可欠です。さらに、ジェネリック注入剤は手ごろな価格であるため、特にヘルスケア・インフラが限られていたりコストが高かったりする低・中所得国では、より多くの人々が入手しやすくなっています。さらに、ヘルスケアシステムは質と費用対効果のバランスを重視しています。これに伴い、ジェネリック注入剤は、必要な治療を先発品に比べ数分の一のコストで提供できるため、実行可能な選択肢となり、より広範な疾病管理と抑制を促進します。

世界中で高まるヘルスケア支出

医療費の増大は、先進国と開発途上国の双方にとって重大な問題です。治療費が高騰しているため、手ごろな価格の代替品が急務となっています。これに伴い、ジェネリック注入剤は有効性や安全性を損なうことなく、費用対効果の高いソリューションを提供します。さらに、患者や家族の経済的負担を大幅に軽減することができます。さらに、ジェネリック医薬品は、予算に制約のあるヘルスケア・システムに余裕を与え、医療サービスの改善、研究、あるいは公衆衛生への取り組みに、より効率的に資源を配分することができます。さらに、患者も自己負担額が減ることで直接恩恵を受け、治療がより身近なものになります。その結果、ヘルスケアコストの上昇により、医療提供者や患者は、財政的に持続可能な代替手段としてジェネリック注入剤に目を向けざるを得なくなっています。

ブランド薬の特許切れの増加

ブランド注射剤の特許満了は、ジェネリック注入剤市場にとって絶好の機会です。特許切れにより、ジェネリック医薬品メーカーはブランド薬のコピーを製造・販売することができます。さらに、ジェネリック医薬品メーカーは、初期の研究開発コストをかけずに同等の医薬品を製造することができるため、その節約分を低価格という形で消費者に還元することができます。さらに、ジェネリック医薬品はすでに承認されている先発医薬品と生物学的に同等であるため、通常、規制当局の承認をより早く受けることができます。これは、市場投入までの時間を短縮するだけでなく、消費者が必要な医薬品を入手する機会を広げることにもなります。さらに、特許の失効により、以前は知的財産権（IP）法によって制限されていた医薬品の大量生産が可能になります。その結果、特許失効はジェネリック注入剤市場の拡大のための環境を整え、メーカーと消費者の双方に利益をもたらします。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界ジェネリック医薬品市場

  • 市場概要
  • 市場実績
  • 市場内訳：地域別
  • 市場予測
  • 主要企業

第6章 世界のジェネリックドラッグデリバリー市場

  • 経口
  • 注射剤
  • 経皮/局所
  • 吸入器

第7章 世界のジェネリック注入剤市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：地域別
  • 市場内訳：治療領域別
  • 市場内訳：容器別
  • 市場内訳：流通チャネル別
  • 市場予測
  • SWOT分析
    • 概要
    • 強み
    • 弱み
    • 機会
    • 脅威
  • バリューチェーン分析
  • ポーターのファイブフォース分析
    • 概要
    • 買い手の交渉力
    • 供給企業の交渉力
    • 競合の程度
    • 新規参入業者の脅威
    • 代替品の脅威
  • 市場促進要因と成功要因

第8章 世界のジェネリック注入剤市場：主要地域の実績

  • 北米
    • 市場動向
    • 市場予測
  • 欧州
    • 市場動向
    • 市場予測
  • アジア
    • 市場動向
    • 市場予測
  • ラテンアメリカ
    • 市場動向
    • 市場予測
  • 中東・アフリカ
    • 市場動向
    • 市場予測

第9章 市場：治療領域別

  • 腫瘍学
    • 市場動向
    • 市場予測
  • 麻酔
    • 市場動向
    • 市場予測
  • 抗感染薬
    • 市場動向
    • 市場予測
  • 経腸栄養
    • 市場動向
    • 市場予測
  • 心臓血管
    • 市場動向
    • 市場予測

第10章 市場：容器別

  • バイアル
    • 市場動向
    • 市場予測
  • アンプル
    • 市場動向
    • 市場予測
  • プレミックス
    • 市場動向
    • 市場予測
  • プレフィルドシリンジ
    • 市場動向
    • 市場予測

第11章 市場：流通チャネル別

  • 病院
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測

第12章 世界のジェネリック注入剤市場：競合情勢

  • 市場構造
  • 市場内訳：主要企業別

第13章 ジェネリック注入剤の製造プロセス

  • 製品概要
  • 詳細なプロセスフロー（注射剤）
  • 様々な種類の単位操作
  • マスバランスと原材料要件

第14章 プロジェクトの詳細・必要条件・費用

  • 土地要件と費用
  • 建設要件と費用
  • 工場の機械
  • 機械写真
  • 原材料の要件と支出
  • 包装の要件と支出
  • 輸送の要件と支出
  • ユーティリティの要件と支出
  • 人員要件と支出
  • その他の設備投資

第15章 融資と資金援助

第16章 プロジェクトの経済性

  • プロジェクトの資本コスト
  • 技術経済的パラメーター
  • サプライチェーンの各段階における製品価格とマージン
  • 課税と減価償却
  • 収入予測
  • 支出予測
  • 財務分析
  • 利益分析

第17章 主要企業のプロファイル

  • Baxter International Inc.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • Sagent Pharmaceuticals Inc.（Nichi-Iko Pharmaceutical Co. Ltd.）
  • Sandoz International GmbH（Novartis International AG）
  • Sanofi S.A.
図表

List of Figures

  • Figure 1: Global: Generic Drug Market: Value Trends (in Billion USD), 2019-2024
  • Figure 2: Global: Generic Drug Market: Breakup by Region (in %), 2024
  • Figure 3: Global: Generic Drug Market Forecast: Value Trends (in Billion USD), 2025-2033
  • Figure 4: Global: Generic Drug Delivery Market: Oral (in Million USD), 2019, 2024 & 2033
  • Figure 5: Global: Generic Drug Delivery Market: Injectables (in Million USD), 2019, 2024 & 2033
  • Figure 6: Global: Generic Drug Delivery Market: Dermal/Topical (in Million USD), 2019, 2024 & 2033
  • Figure 7: Global: Generic Drug Delivery Market: Inhalers (in Million USD), 2019, 2024 & 2033
  • Figure 8: Global: Generic Injectables Market: Value Trends (in Billion USD), 2019-2024
  • Figure 9: Global: Generic Injectables Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Generic Injectables Market: Breakup by Therapeutic Area (in %), 2024
  • Figure 11: Global: Generic Injectables Market: Breakup by Container (in %), 2024
  • Figure 12: Global: Generic Injectables Market: Breakup by Distribution Channel (in %), 2024
  • Figure 13: Global: Generic Injectables Market Forecast: Value Trends (in Billion USD), 2025-2033
  • Figure 14: Global: Generic Injectables Industry: SWOT Analysis
  • Figure 15: Global: Generic Injectables Industry: Value Chain Analysis
  • Figure 16: Global: Generic Injectables Industry: Porter's Five Forces Analysis
  • Figure 17: North America: Generic Injectables Market (in Million USD), 2019 & 2024
  • Figure 18: North America: Generic Injectables Market Forecast (in Million USD), 2025-2033
  • Figure 19: Europe: Generic Injectables Market (in Million USD), 2019 & 2024
  • Figure 20: Europe: Generic Injectables Market Forecast (in Million USD), 2025-2033
  • Figure 21: Asia: Generic Injectables Market (in Million USD), 2019 & 2024
  • Figure 22: Asia: Generic Injectables Market Forecast (in Million USD), 2025-2033
  • Figure 23: Latin America: Generic Injectables Market (in Million USD), 2019 & 2024
  • Figure 24: Latin America: Generic Injectables Market Forecast (in Million USD), 2025-2033
  • Figure 25: Middle East and Africa: Generic Injectables Market (in Million USD), 2019 & 2024
  • Figure 26: Middle East and Africa: Generic Injectables Market Forecast (in Million USD), 2025-2033
  • Figure 27: Global: Generic Injectables (Oncology) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 28: Global: Generic Injectables (Oncology) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 29: Global: Generic Injectables (Anaesthesia) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 30: Global: Generic Injectables (Anaesthesia) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 31: Global: Generic Injectables (Anti-infectives) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 32: Global: Generic Injectables (Anti-infectives) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 33: Global: Generic Injectables (Parenteral Nutrition) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 34: Global: Generic Injectables (Parenteral Nutrition) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 35: Global: Generic Injectables (Cardiovascular) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 36: Global: Generic Injectables (Cardiovascular) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 37: Global: Generic Injectables (Vials) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 38: Global: Generic Injectables (Vials) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 39: Global: Generic Injectables (Ampoules) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 40: Global: Generic Injectables (Ampoules) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 41: Global: Generic Injectables (Premix) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 42: Global: Generic Injectables (Premix) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 43: Global: Generic Injectables (Prefilled Syringes) Market: Value Trends (in Million USD), 2019 & 2024
  • Figure 44: Global: Generic Injectables (Prefilled Syringes) Market Forecast: Value Trends (in Million USD), 2025-2033
  • Figure 45: Global: Generic Injectables Market: Sales through Hospitals (in Million USD), 2019 & 2024
  • Figure 46: Global: Generic Injectables Market Forecast: Sales through Hospitals (in Million USD), 2025-2033
  • Figure 47: Global: Generic Injectables Market: Sales through Retail Pharmacy (in Million USD), 2019 & 2024
  • Figure 48: Global: Generic Injectables Market Forecast: Sales through Retail Pharmacy (in Million USD), 2025-2033
  • Figure 49: Generic Injectables Manufacturing Process: Conversion Rate of Feedstocks
  • Figure 50: Generic Injectables Manufacturing: Detailed Process Flow
  • Figure 51: Generic Injectables Manufacturing: Production Cost Breakup (in %)
  • Figure 52: Generic Injectables Industry: Profit Margins at Various Levels of the Supply Chain
  • Figure 53: Generic Injectables Manufacturing Plant: Proposed Plant Layout
  • Figure 54: Generic Injectables Manufacturing Plant: Breakup of Capital Costs (in %)

List of Tables

  • Table 1: Global: Generic Drug Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Generic Drug Market Forecast: Breakup by Region, 2025-2033
  • Table 3: Global: Generic Drug Market: Revenues of Key Players (in Million USD), 2019
  • Table 4: Global: Generic Injectables Market: Key Industry Highlights, 2024 and 2033
  • Table 5: Global: Generic Injectables Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Generic Injectables Market Forecast: Breakup by Therapeutic Area (in Million USD), 2025-2033
  • Table 7: Global: Generic Injectables Market Forecast: Breakup by Container (in Million USD), 2025-2033
  • Table 8: Global: Generic Injectables Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 9: Generic Injectables Manufacturing Plant: Costs Related to Land and Site Development (in USD)
  • Table 10: Generic Injectables Manufacturing Plant: Costs Related to Civil Works (in USD)
  • Table 11: Generic Injectables Manufacturing Plant: Costs Related to Machinery Unit (in USD)
  • Table 12: Generic Injectables Manufacturing Plant: Raw Material Requirements (Kg/Day) and Expenditures (USD/Kg)
  • Table 13: Generic Injectables Manufacturing Plant: Costs Related to Salaries and Wages (in USD)
  • Table 14: Generic Injectables Manufacturing Plant: Costs Related to Other Capital Investments (in USD)
  • Table 15: Details of Financial Assistance Offered by Financial Institutions
  • Table 16: Generic Injectables Manufacturing Plant: Capital Costs (in USD)
  • Table 17: Generic Injectables Manufacturing Plant: Techno-Economic Parameters (in USD)
  • Table 18: Generic Injectables Manufacturing Plant: Taxation and Depreciation (in USD)
  • Table 19: Generic Injectables Manufacturing Plant: Income Projections (in USD)
  • Table 20: Generic Injectables Manufacturing Plant: Expenditure Projections (in USD)
  • Table 21: Generic Injectables Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability (in USD)
  • Table 22: Generic Injectables Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability (in USD)
  • Table 23: Generic Injectables Manufacturing Plant: Profit and Loss Account (in USD)
目次
Product Code: SR112024A804

The global generic injectables market size reached USD 51.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 99.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.88% during 2025-2033. The growing patent expiration of branded drugs, along with the increasing regulatory support from government bodies, is primarily driving the market.

Generic injectables refer to pharmaceutical drugs that are injected into the body and are equivalent to their brand-name counterparts in dosage, strength, quality, and performance. It includes various types, such as vaccines, insulin, and antibiotics. Generic injectables are widely used for a range of medical conditions, such as diabetes, cancer, hypertension, and infections. They also find extensive applications in anesthesia, hormone replacement, immunization, and emergency treatments. Generic injectables are safe and cost-effective medications that reduce the need for surgical interventions, provide targeted therapy, and have fewer side effects.

The recent technological advancements in drug formulation and delivery systems that are making production more efficient, thereby lowering costs and boosting availability, are propelling the market growth. Additionally, the implementation of various regulatory support and initiatives to create a conducive environment for manufacturers of generic injectables by streamlining approval processes is contributing to the market growth. Apart from this, the growing geriatric population, which requires more healthcare interventions, including injectables for various age-related ailments, is positively influencing the market growth. Furthermore, the rising preference for injectables over oral medications among patients due to quicker onset of action and higher bioavailability is strengthening the market growth. In addition, the rapid improvement in the supply chain, which has made the distribution of generic injectables more streamlined, is supporting the market growth.

Generic Injectables Market Trends/Drivers:

The escalating prevalence of chronic diseases

The escalating prevalence of chronic diseases is a primary driver of the generic injectables market. Conditions such as cancer, diabetes, and cardiovascular diseases (CVDs) are on a constant rise and require long-term treatments and medications. Generic injectables such as insulin for diabetes, chemotherapeutic agents for cancer, and antihypertensive medications for cardiovascular issues are indispensable in the management of these conditions. Furthermore, the affordability of generic injectables makes them accessible to a larger population, especially in low and middle-income countries where healthcare infrastructure may be limited or costly. Additionally, healthcare systems are focusing on balancing quality and cost-effectiveness. In line with this, generic injectables present a viable option, as they provide the necessary treatments at a fraction of the cost of their branded counterparts, thus facilitating more widespread disease management and containment.

The rising healthcare expenditure across the globe

The growing cost of healthcare is a significant concern for both developed and developing nations. There is an urgent need for affordable alternatives as treatment expenses are skyrocketing. In line with this, generic injectables offer a cost-effective solution without compromising on efficacy or safety. Furthermore, they can substantially lower the economic burden on patients and families. Additionally, they provide budget-constrained healthcare systems with the leeway to allocate resources more efficiently towards the improvement of healthcare services, research, or public health initiatives. Moreover, patients also benefit directly through lower out-of-pocket costs, making treatments more accessible. As a result, the rising cost of healthcare is compelling healthcare providers and patients to turn to generic injectables as a financially sustainable alternative.

The increasing patent expiration of branded drugs

Patent expirations of branded injectables present a golden opportunity for the generic injectables market. Expiry of the patent allows generic drug manufacturers to produce and sell copies of the branded medication. Furthermore, they can produce equivalent medications without incurring the initial research and development (R&D) costs, thereby passing on the savings to the consumers in the form of lower prices. Moreover, the generic versions usually receive faster regulatory approvals as they are bioequivalent to already-approved branded drugs. This not only speeds up the time-to-market but also broadens consumer access to essential medications. Additionally, patent expiry enables the mass production of medications that were previously restricted by intellectual property (IP) laws. As a result, patent expiration creates a conducive environment for the expansion of the generic injectables market, benefiting both manufacturers and consumers.

Generic Injectables Industry Segmentation:

Breakup by Therapeutic Area:

Oncology

Anaesthesia

Anti-infectives

Parenteral Nutrition

Cardiovascular

Oncology dominates the market

Oncology is dominating the market due to the high prevalence of cancer, which necessitates a consistent and accessible supply of medications for treatment. Furthermore, cancer treatments are highly expensive, often requiring combinations of drugs and long-term administration. In line with this, generic injectables offer a cost-effective alternative to branded drugs, alleviating some of the financial burdens on healthcare systems and patients. Besides this, the oncology sector has witnessed patent expirations for branded drugs, thus opening up opportunities for generic pharmaceutical companies to introduce their versions of these medications. Moreover, the complexity of cancer treatment protocols, which often call for targeted therapies, is facilitating the demand for generic injectables. In addition, oncology treatments frequently necessitate hospitalization or clinical administration of drugs, where injectables are more commonly used.

Breakup by Container:

Vials

Ampoules

Premix

Prefilled Syringes

Vials exhibit a clear dominance in the market

Vials offer a high degree of sterility and contamination protection, which is essential for injectable drugs. The integrity of the medication is better preserved in a vial, which is a critical factor when dealing with sensitive substances, such as biologics or chemotherapy agents. Furthermore, they are incredibly versatile and can accommodate a wide range of drug volumes, from small quantities for specialized treatments to larger volumes for widespread applications. Additionally, vials are highly cost-effective, especially when produced in bulk. This cost advantage aligns well with the overall appeal of generic injectables as cost-effective alternatives to branded drugs.

Ampoules offer high barrier properties, ensuring that the medication inside remains sterile and free from contamination. Additionally, the glass construction of ampoules allows for high visibility, enabling healthcare professionals to visually inspect the solution for any impurities before administration, thus adding an extra layer of safety. Besides this, they are usually single-dose containers, which eliminates the risks associated with multi-dose vials, such as cross-contamination and dosing errors.

Breakup by Distribution Channel:

Hospitals

Retail Pharmacy

Hospitals holds the largest share in the market

Hospitals are dominating the market as they allow the immediate and precise administration of injectables, which is especially critical in emergency situations or intensive care units (ICUs) where quick onset of action can be lifesaving. Furthermore, they handle a high volume of patients and a broad array of medical conditions, ranging from surgeries to chronic disease management. The versatility of generic injectables allows them to be used across various departments, making them a go-to option for multiple therapeutic applications. Besides this, hospitals have the necessary infrastructure, including temperature-controlled storage and trained medical staff, to manage the complexities of injectable drug administration. Moreover, the growing pressure to manage healthcare costs effectively makes generic injectables a preferred choice for hospitals.

Breakup by Region:

Europe

North America

Asia

Latin America

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest generic injectables market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a well-established healthcare system that readily adopts medical innovations, including generic injectables. Furthermore, the region has some of the highest per capita healthcare spending, allowing for the widespread use of both branded and generic pharmaceuticals. Additionally, the imposition of supportive policies by regional governments to streamline processes for the approval of generic medications, including injectables, is positively influencing the market growth. Besides this, the frequent expiry of branded medication patents in North America is creating opportunities for generic drug manufacturers to introduce their own, more affordable versions. Moreover, the escalating geriatric population, which requires more medical treatments, often leading to higher consumption of medications, including injectables, is acting as another growth-inducing factor. Along with this, the heightened awareness and acceptance among both healthcare providers and consumers regarding the efficacy and cost-effectiveness of generic medications is supporting the market growth.

Competitive Landscape:

Leading companies are consistently working to expand their range of generic injectable medications, including biosimilars, to cover a broader spectrum of therapeutic areas. Furthermore, they are investing in research and innovation to improve the formulation and stability of generic injectables, thereby enhancing their quality and market appeal. In addition, several key players are forming strategic partnerships with other industry stakeholders to enhance their capabilities, distribution networks, and product offerings. Besides this, companies are focusing on expanding their geographical reach through collaboration with local distributors or setting up manufacturing facilities. Additionally, they are working on optimizing their production processes to offer cost-effective solutions without compromising on quality. Moreover, major players are ensuring products meet the rigorous regulatory requirements, especially in highly regulated markets.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Baxter International Inc.

Fresenius Kabi AG

Hikma Pharmaceuticals plc

Pfizer Inc.

Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.)

Sandoz International GmbH (Novartis International AG)

Sanofi S.A.

Key Questions Answered in This Report

  • 1. What was the size of the global generic injectables market in 2024?
  • 2. What is the expected growth rate of the global generic injectables market during 2025-2033?
  • 3. What has been the impact of COVID-19 on the global generic injectables market?
  • 4. What are the key factors driving the global generic injectables market?
  • 5. What is the breakup of the global generic injectables market based on the therapeutic area?
  • 6. What is the breakup of the global generic injectables market based on the distribution channel?
  • 7. What are the key regions in the global generic injectables market?
  • 8. Who are the key players/companies in the global generic injectables market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Generic Drug Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Breakup by Region
  • 5.4 Market Forecast
  • 5.5 Major Players

6 Global Generic Drug Delivery Market

  • 6.1 Oral
  • 6.2 Injectables
  • 6.3 Dermal/Topical
  • 6.4 Inhalers

7 Global Generic Injectables Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Impact of COVID-19
  • 7.4 Market Breakup by Region
  • 7.5 Market Breakup by Therapeutic Area
  • 7.6 Market Breakup by Container
  • 7.7 Market Breakup by Distribution Channel
  • 7.8 Market Forecast
  • 7.9 SWOT Analysis
    • 7.9.1 Overview
    • 7.9.2 Strengths
    • 7.9.3 Weaknesses
    • 7.9.4 Opportunities
    • 7.9.5 Threats
  • 7.10 Value Chain Analysis
  • 7.11 Porter's Five Forces Analysis
    • 7.11.1 Overview
    • 7.11.2 Bargaining Power of Buyers
    • 7.11.3 Bargaining Power of Suppliers
    • 7.11.4 Degree of Competition
    • 7.11.5 Threat of New Entrants
    • 7.11.6 Threat of Substitutes
  • 7.12 Key Market Drivers and Success Factors

8 Global Generic Injectables Market: Performance of Key Regions

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market by Therapeutic Area

  • 9.1 Oncology
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Anaesthesia
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Anti-infectives
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Parenteral Nutrition
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Cardiovascular
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market by Container

  • 10.1 Vials
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Ampoules
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Premix
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Prefilled Syringes
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market by Distribution Channel

  • 11.1 Hospitals
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacy
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast

12 Global Generic Injectables Market: Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Market Breakup by Key Players

13 Generic Injectables Manufacturing Process

  • 13.1 Product Overview
  • 13.2 Detailed Process Flow (Injectables)
  • 13.3 Various Types of Unit Operations Involved
  • 13.4 Mass Balance and Raw Material Requirements

14 Project Details, Requirements and Costs Involved

  • 14.1 Land Requirements and Expenditures
  • 14.2 Construction Requirements and Expenditures
  • 14.3 Plant Machinery
  • 14.4 Machinery Pictures
  • 14.5 Raw Material Requirements and Expenditures
  • 14.6 Packaging Requirements and Expenditures
  • 14.7 Transportation Requirements and Expenditures
  • 14.8 Utility Requirements and Expenditures
  • 14.9 Manpower Requirements and Expenditures
  • 14.10 Other Capital Investments

15 Loans and Financial Assistance

16 Project Economics

  • 16.1 Capital Cost of the Project
  • 16.2 Techno-Economic Parameters
  • 16.3 Product Pricing and Margins Across Various Levels of the Supply Chain
  • 16.4 Taxation and Depreciation
  • 16.5 Income Projections
  • 16.6 Expenditure Projections
  • 16.7 Financial Analysis
  • 16.8 Profit Analysis

17 Key Player Profiles

  • 17.1 Baxter International Inc.
    • 17.1.1 Company Overview
    • 17.1.2 Product Portfolio
    • 17.1.3 Financials
    • 17.1.4 SWOT Analysis
  • 17.2 Fresenius Kabi AG
    • 17.2.1 Company Overview
    • 17.2.2 Product Portfolio
    • 17.2.3 Financials
    • 17.2.4 SWOT Analysis
  • 17.3 Hikma Pharmaceuticals plc
    • 17.3.1 Company Overview
    • 17.3.2 Product Portfolio
    • 17.3.3 Financials
    • 17.3.4 SWOT Analysis
  • 17.4 Pfizer Inc.
    • 17.4.1 Company Overview
    • 17.4.2 Product Portfolio
    • 17.4.3 Financials
    • 17.4.4 SWOT Analysis
  • 17.5 Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.)
    • 17.5.1 Company Overview
    • 17.5.2 Product Portfolio
    • 17.5.3 Financials
    • 17.5.4 SWOT Analysis
  • 17.6 Sandoz International GmbH (Novartis International AG)
    • 17.6.1 Company Overview
    • 17.6.2 Product Portfolio
    • 17.6.3 Financials
    • 17.6.4 SWOT Analysis
  • 17.7 Sanofi S.A.
    • 17.7.1 Company Overview
    • 17.7.2 Product Portfolio
    • 17.7.3 Financials
    • 17.7.4 SWOT Analysis